 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of [0m
[34mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase or decrease the risk of [0m
[32mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"WARFARIN"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: WARFARIN: clinical_studies: Table [0m[1;31m5[0m[31m: Prospective, Randomized, Open-Label, Positive-Controlled Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart Valves Patients Treated [0m
[31mWith Warfarin Dipyridamole/Aspirin Pentoxifylline/Aspirin Event Thromboembolism [0m[1;31m2.2[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m8.6[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m7.9[0m[31m/[0m[1;31m100[0m[31m py Major Bleeding [0m[1;31m2.5[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m0[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m0.9[0m[31m/[0m[1;31m100[0m[31m py py = patient years In a prospective, [0m
[31mopen-label, clinical study comparing moderate [0m[1;31m([0m[31mINR [0m[1;31m2.65[0m[1;31m)[0m[31m versus high intensity [0m[1;31m([0m[31mINR [0m[1;31m9[0m[1;31m)[0m[31m warfarin therapies in [0m[1;31m258[0m[31m patients with mechanical prosthetic heart valves, thromboembolism occurred with similar[0m
[31mfrequency in the two groups [0m[1;31m([0m[1;31m4[0m[31m and [0m[1;31m3.7[0m[31m events per [0m[1;31m100[0m[31m patient years, respectively[0m[1;31m)[0m[31m. Major bleeding was more common in the high intensity group. WARFARIN: clinical_studies: The results of this study [0m
[31mare presented in Table [0m[1;31m6[0m[31m . Table [0m[1;31m6[0m[31m: Prospective, Open-Label Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart Valves Event Moderate Warfarin Therapy INR [0m[1;31m2.65[0m[31m High Intensity [0m
[31mWarfarin Therapy INR [0m[1;31m9[0m[31m Thromboembolism [0m[1;31m4[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m3.7[0m[31m/[0m[1;31m100[0m[31m py Major Bleeding [0m[1;31m0.95[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m2.1[0m[31m/[0m[1;31m100[0m[31m py py = patient years In a randomized trial in [0m[1;31m210[0m[31m patients comparing two intensities of warfarin therapy [0m
[1;31m([0m[31mINR [0m[1;31m2[0m[31m to [0m[1;31m2.25[0m[31m vs. INR [0m[1;31m2.5[0m[31m to [0m[1;31m4[0m[1;31m)[0m[31m for a three month period following tissue heart valve replacement, thromboembolism occurred with similar frequency in the two groups [0m[1;31m([0m[31mmajor embolic events [0m[1;31m2[0m[31m% vs. [0m[1;31m1.9[0m[31m%,[0m
[31mrespectively, and minor embolic events [0m[1;31m10.8[0m[31m% vs. [0m[1;31m10.2[0m[31m%, respectively[0m[1;31m)[0m[31m. WARFARIN: clinical_studies: Major hemorrhages occurred in [0m[1;31m4.6[0m[31m% of patients in the higher intensity INR group compared to zero in [0m
[31mthe lower intensity INR group. [0m[1;31m14.3[0m[31m Myocardial Infarction WARIS [0m[1;31m([0m[31mThe Warfarin Re-Infarction Study[0m[1;31m)[0m[31m was a double-blind, randomized study of [0m[1;31m1214[0m[31m patients [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m weeks post-infarction treated with [0m
[31mwarfarin to a target INR of [0m[1;31m2.8[0m[31m to [0m[1;31m4.8[0m[31m. The primary endpoint was a composite of total mortality and recurrent infarction. A secondary endpoint of cerebrovascular events was assessed. Mean follow-up of[0m
[31mthe patients was [0m[1;31m37[0m[31m months. The results for each endpoint separately, including an analysis of vascular death, are provided in Table [0m[1;31m7[0m[31m . WARFARIN: clinical_studies: Table [0m[1;31m7[0m[31m: WARIS â€“ Endpoint Analysis [0m
[31mof Separate Events % Risk Warfarin Placebo Reduction Event [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m RR [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m [0m[1;31m([0m[31m p -value[0m[1;31m)[0m[31m Total Patient Years of Follow-up [0m[1;31m2018[0m[31m [0m[1;31m1944[0m[31m Total Mortality [0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m123[0m[31m [0m[1;31m([0m[1;31m6.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.76[0m[31m [0m
[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m0.97[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.030[0m[1;31m)[0m[31m Vascular Death [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m5.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.78[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m1.02[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m Recurrent MI [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: [0m
[31mclinical_studies: [0m[1;31m001[0m[1;31m)[0m[31m Cerebrovascular Event [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m [0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.002[0m[1;31m)[0m[31m RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = Confidence interval; MI = Myocardial [0m
[31minfarction; py = patient years WARIS II [0m[1;31m([0m[31mThe Warfarin, Aspirin, Re-Infarction Study[0m[1;31m)[0m[31m was an open-label, randomized study of [0m[1;31m3630[0m[31m patients hospitalized for acute myocardial infarction treated with [0m
[31mwarfarin to a target INR [0m[1;31m2.8[0m[31m to [0m[1;31m4.2[0m[31m, aspirin [0m[1;31m160[0m[31m mg per day, or warfarin to a target INR [0m[1;31m2[0m[31m to [0m[1;31m2.5[0m[31m plus aspirin [0m[1;31m75[0m[31m mg per day prior to hospital discharge. The primary endpoint was a composite of death,[0m
[31mnonfatal reinfarction, or thromboembolic stroke. WARFARIN: clinical_studies: The mean duration of observation was approximately [0m[1;31m4[0m[31m years. The results for WARIS II are provided in Table [0m[1;31m8[0m[31m . Table [0m[1;31m8[0m[31m: [0m
[31mWARIS II â€“ Distribution of Events According to Treatment Group Event Aspirin [0m[1;31m([0m[31mN = [0m[1;31m1206[0m[1;31m)[0m[31m Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1216[0m[1;31m)[0m[31m Aspirin plus Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1208[0m[1;31m)[0m[31m Rate Ratio [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m p -value No. of Events Major Bleeding a[0m
[1;31m8[0m[31m [0m[1;31m33[0m[31m [0m[1;31m28[0m[31m [0m[1;31m3.35[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m4.00[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Minor Bleeding d [0m[1;31m39[0m[31m [0m[1;31m103[0m[31m [0m[1;31m133[0m[31m [0m[1;31m3.21[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m2.55[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Composite Endpoints e [0m[1;31m241[0m[31m [0m[1;31m203[0m[31m [0m[1;31m181[0m[31m [0m[1;31m0.81[0m[31m [0m[1;31m([0m[1;31m0.69[0m[31m to [0m[1;31m0.95[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.71[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m to [0m[1;31m0.83[0m[1;31m)[0m[31m c [0m[1;31m0[0m[31m. WARFARIN: [0m
[31mclinical_studies: [0m[1;31m001[0m[31m Reinfarction [0m[1;31m117[0m[31m [0m[1;31m90[0m[31m [0m[1;31m69[0m[31m [0m[1;31m0.56[0m[31m [0m[1;31m([0m[1;31m0.41[0m[31m to [0m[1;31m0.78[0m[1;31m)[0m[31m b [0m[1;31m<[0m[31m [0m[1;31m0.001[0m[31m [0m[1;31m0.74[0m[31m [0m[1;31m([0m[1;31m0.55[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Thromboembolic Stroke [0m[1;31m32[0m[31m [0m[1;31m17[0m[31m [0m[1;31m17[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.97[0m[1;31m)[0m[31m c [0m[1;31m0.03[0m[31m Death [0m[1;31m92[0m[31m [0m[1;31m96[0m[31m [0m
[1;31m95[0m[31m [0m[1;31m0.82[0m[31m a Major bleeding episodes were defined as nonfatal cerebral hemorrhage or bleeding necessitating surgical intervention or blood transfusion. b The rate ratio is for aspirin plus warfarin as [0m
[31mcompared with aspirin. c The rate ratio is for warfarin as compared with aspirin. d Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood [0m
[31mtransfusion. WARFARIN: clinical_studies: e Includes death, nonfatal reinfarction, and thromboembolic cerebral stroke. CI = confidence interval ND = not determined There were approximately four times [0m
[31mas many major bleeding episodes in the two groups receiving warfarin than in the group receiving aspirin alone. Major bleeding episodes were not more frequent among patients receiving aspirin plus [0m
[31mwarfarin than among those receiving warfarin alone, but the incidence of minor bleeding episodes was higher in the combined therapy group.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism [0m[1;31m([0m[31mPE[0m[1;31m)[0m[31m. [0m
[31mProphylaxis and treatment of thromboembolic complications associated with atrial fibrillation [0m[1;31m([0m[31mAF[0m[1;31m)[0m[31m and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction [0m
[1;31m([0m[31mMI[0m[1;31m)[0m[31m, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. Limitations of Use Warfarin sodium tablets have no direct effect on an established thrombus, nor [0m
[31mdoes it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary [0m
[31mthromboembolic complications that may result in serious and possibly fatal sequelae. WARFARIN: indications_and_usage: Warfarin sodium tablets are a vitamin K antagonist indicated for: Prophylaxis and [0m
[31mtreatment of venous thrombosis and its extension, pulmonary embolism [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve [0m
[31mreplacement [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m Limitations of [0m
[31mUse Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies_table: [0m[1;31m35[0m[31m<sup>b<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>ND<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td[0m
[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m4.00[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>ND<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mrowspan[0m[31m=[0m[31m"2"[0m[31m><paragraph>Minor Bleeding<sup>d<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m39[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m103[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m133[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m3[0m[31m. WARFARIN: [0m
[31mclinical_studies_table: [0m[1;31m21[0m[31m<sup>b<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>ND<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m2.55[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>ND<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mrowspan[0m[31m=[0m[31m"2"[0m[31m><paragraph>Composite Endpoints<sup>e<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td[0m
[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m241[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m203[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m181[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.81[0m[31m [0m[1;31m([0m[1;31m0.69[0m[31m to [0m
[1;31m0.95[0m[1;31m)[0m[31m<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m[1;31m03[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.71[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m to [0m[1;31m0.83[0m[1;31m)[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.001[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mrowspan[0m[31m=[0m[31m"2"[0m[31m><paragraph> Reinfarction <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m117[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m69[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.56[0m[31m [0m[1;31m([0m[1;31m0.41[0m[31m to [0m
[1;31m0.78[0m[1;31m)[0m[31m<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>&lt; [0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m[1;31m001[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.74[0m[31m [0m[1;31m([0m[1;31m0.55[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.03[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mrowspan[0m[31m=[0m[31m"2"[0m[31m><paragraph> Thromboembolic Stroke [0m
[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m32[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m17[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m17[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.52[0m[31m [0m
[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.98[0m[1;31m)[0m[31m<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m[1;31m03[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.52[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m to [0m[1;31m0.97[0m[1;31m)[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m><paragraph>[0m[1;31m0.03[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Botrule"[0m[31m><paragraph> Death [0m
[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule"[0m[31m><paragraph>[0m[1;31m92[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule"[0m[31m><paragraph>[0m[1;31m96[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" [0m
[31mBotrule"[0m[31m><paragraph>[0m[1;31m95[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule"[0m[31m><paragraph>[0m[1;31m0[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies_table: [0m[1;31m02[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>Recurrent [0m
[31mMI <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m
[1;31m001[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>Cerebrovascular Event <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>[0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" [0m
[31mToprule"[0m[31m><paragraph>[0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies_table: [0m[1;31m002[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mcolspan[0m[31m=[0m[31m"5"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Toprule"[0m[31m><paragraph>RR = Relative risk; Risk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = [0m
[31mConfidence interval; MI = Myocardial infarction; py = patient years <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: openfda: spl_id         [0m
[31mSOURCE:WARFARIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: WARFARIN is indicated for the reduction in the risk of death, recurrent myocardial infarction [0m[1;32m([0m[32mMI[0m[1;32m)[0m[32m, and thromboembolic events such as stroke or systemic embolization after myocardial [0m
[32minfarction. In the Warfarin Re-Infarction Study [0m[1;32m([0m[32mWARIS[0m[1;32m)[0m[32m, treatment with warfarin to a target INR of [0m[1;32m2.8[0m[32m to [0m[1;32m4.8[0m[32m showed a [0m[1;32m24[0m[32m% risk reduction in total mortality [0m[1;32m([0m[32mp = [0m[1;32m0.030[0m[1;32m)[0m[32m and a [0m[1;32m34[0m[32m% risk reduction in [0m
[32mrecurrent MI [0m[1;32m([0m[32mp = [0m[1;32m0.001[0m[1;32m)[0m[32m compared to placebo. The study also reported a [0m[1;32m54[0m[32m% risk reduction in cerebrovascular events [0m[1;32m([0m[32mp = [0m[1;32m0.002[0m[1;32m)[0m[32m. These results suggest that warfarin decreases the risk of mortality [0m
[32mafter myocardial infarction.[0m
[32mSOURCE: WARFARIN label[0m
[32mEXTRACT_START_END: WARFARIN: clinical_studies: The results[0m[32m...[0m[32m [0m[1;32m([0m[32mp = [0m[1;32m0.030[0m[1;32m)[0m[32m Vascular Death[0m[32m...[0m
*[1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: WARFARIN is indicated for the reduction in [0m
[34mthe risk of death, recurrent myocardial infarction [0m[1;34m([0m[34mMI[0m[1;34m)[0m[34m, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. In the Warfarin Re-Infarction Study [0m[1;34m([0m[34mWARIS[0m[1;34m)[0m[34m, [0m
[34mtreatment with warfarin to a target INR of [0m[1;34m2.8[0m[34m to [0m[1;34m4.8[0m[34m showed a [0m[1;34m24[0m[34m% risk reduction in total mortality [0m[1;34m([0m[34mp = [0m[1;34m0.030[0m[1;34m)[0m[34m and a [0m[1;34m34[0m[34m% risk reduction in recurrent MI [0m[1;34m([0m[34mp = [0m[1;34m0.001[0m[1;34m)[0m[34m compared to placebo. The study [0m
[34malso reported a [0m[1;34m54[0m[34m% risk reduction in cerebrovascular events [0m[1;34m([0m[34mp = [0m[1;34m0.002[0m[1;34m)[0m[34m. These results suggest that warfarin decreases the risk of mortality after myocardial infarction.[0m
[34mSOURCE: WARFARIN label[0m
[34mEXTRACT_START_END: WARFARIN: clinical_studies: The results[0m[34m...[0m[34m [0m[1;34m([0m[34mp = [0m[1;34m0.030[0m[1;34m)[0m[34m Vascular Death[0m[34m...[0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether WARFARIN increases or decreases the risk of mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded by indicating that WARFARIN is indicated for the reduction in the risk of death after myocardial infarction. In the Warfarin Re-Infarction Study [0m[32m([0m[32mWARIS[0m[32m)[0m[32m, treatment with [0m
[32mwarfarin showed a 24% risk reduction in total mortality compared to placebo."[0m[32m,[0m
[32m      [0m[32m"The FDA label for WARFARIN, as provided by FDAHandler, supports the conclusion that WARFARIN decreases the risk of mortality after myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"WARFARIN decreases the risk of mortality after myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does WARFARIN increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether WARFARIN increases or decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded by indicating that WARFARIN is indicated for the reduction in the risk of death after myocardial infarction. In the Warfarin Re-Infarction Study [0m[34m([0m[34mWARIS[0m[34m)[0m[34m, treatment with [0m
[34mwarfarin showed a 24% risk reduction in total mortality compared to placebo."[0m[34m,[0m
[34m      [0m[34m"The FDA label for WARFARIN, as provided by FDAHandler, supports the conclusion that WARFARIN decreases the risk of mortality after myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"WARFARIN decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does WARFARIN increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether WARFARIN increases or decreases the risk of mortality after myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded by indicating that WARFARIN is indicated for the reduction in the risk of death after myocardial infarction. In the Warfarin Re-Infarction Study [0m[1;31m([0m[31mWARIS[0m[1;31m)[0m[31m, treatment with [0m
[31mwarfarin showed a [0m[1;31m24[0m[31m% risk reduction in total mortality compared to placebo.[0m
[1;31m3[0m[31m. The FDA label for WARFARIN, as provided by FDAHandler, supports the conclusion that WARFARIN decreases the risk of mortality after myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: WARFARIN decreases the risk of mortality after myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent with medical knowledge and logical reasoning. The user has cited a specific study [0m[32m([0m[32mWARIS[0m[32m)[0m[32m that supports the conclusion, and the information is [0m
[32mcorroborated by the FDA label for WARFARIN. The strength of evidence and the magnitude of the effect [0m[32m([0m[32m24% risk reduction[0m[32m)[0m[32m are clearly expressed. There are no identifiable flaws in the reasoning [0m
[32mprocess."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent with medical knowledge and logical reasoning. The user has cited a specific study [0m[34m([0m[34mWARIS[0m[34m)[0m[34m that supports the conclusion, and the information is [0m
[34mcorroborated by the FDA label for WARFARIN. The strength of evidence and the magnitude of the effect [0m[34m([0m[34m24% risk reduction[0m[34m)[0m[34m are clearly expressed. There are no identifiable flaws in the reasoning [0m
[34mprocess."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent with medical knowledge and logical reasoning. The user has cited a specific study [0m[1;31m([0m[31mWARIS[0m[1;31m)[0m[31m that supports the conclusion, and the information is [0m
[31mcorroborated by the FDA label for WARFARIN. The strength of evidence and the magnitude of the effect [0m[1;31m([0m[1;31m24[0m[31m% risk reduction[0m[1;31m)[0m[31m are clearly expressed. There are no identifiable flaws in the reasoning [0m
[31mprocess.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mWARFARIN decreases the risk of mortality after myocardial infarction. This conclusion is based on the Warfarin Re-Infarction Study [0m[1;32m([0m[32mWARIS[0m[1;32m)[0m[32m, which showed that treatment with warfarin led to a [0m[1;32m24[0m[32m% risk [0m
[32mreduction in total mortality compared to placebo. The FDA label for WARFARIN confirms its indication for reducing the risk of death after myocardial infarction.[0m
